Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance

Plus: Japan Passes Bill For Free Vaccines

Executive Summary

Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.

You may also be interested in...



Novartis Steps Up To Plate To Produce Pfizer/BioNTech COVID-19 Vaccine

In the latest example of cross-industry collaboration in these turbulent times, Novartis is joining forces with Pfizer and BioNTech to help produce their in-demand mRNA vaccine at a facility in Switzerland.

Novartis’s JAK Inhibitor Fails In COVID, Raising Questions On Lilly Prospects

The Phase III failure of ruxolotinib contrasts with encouraging results and emergency use authorization for Lilly’s JAK inhibitor baricitinib in combination therapy.

Novartis’s Canakinumab Fails In COVID-19 Pneumonia Patients

Drug fails to save lives in study and follows disappointments from Roche and Regeneron/Sanofi's IL-6 inhibitors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel